Physicians who received gifts from pharmaceutical companies related to opioid medications were more likely to prescribe opioids to their patients the following year, compared to physicians who did not receive such gifts, according to a new analysis led by health policy scientists at the University of Pittsburgh Graduate School of Public Health.
09:06
Pediatric Research, Published online: 29 October 2019; doi:10.1038/s41390-019-0645-8Program implementation gaps and ethical issues in the prevention of HIV infection among infants, children, and adolescents in sub-Saharan Africa
Tue Oct 29, 2019 02:00
Pediatric Research, Published online: 29 October 2019; doi:10.1038/s41390-019-0637-8Correction: Inflammatory markers and bone mass in children with overweight/obesity: the role of muscular fitness
Tue Oct 29, 2019 02:00
Pediatric Research, Published online: 29 October 2019; doi:10.1038/s41390-019-0652-9When a neonatologist become the father of a NICU baby: How do I feel and how did I change?
Tue Oct 29, 2019 02:00
Pediatric Research, Published online: 28 October 2019; doi:10.1038/s41390-019-0642-yECI biocommentary—February 2020
Mon Oct 28, 2019 02:00
Abstract The objective of this study is to investigate the need for detailed classification of skin colors through the quantification of skin color and light absorbance differences. Skin color is one of the most important factors in dermatological laser treatments. Dermatological laser treatments are currently performed based on the experience and judgment of the doctor with the Fitzpatrick scale. However, the Fitzpatrick scale and the doctor’s experience were not quantified assessment...
02:00
Abstract The main purpose of this work was to construct an energy-dependent response curve of photobiomodulation on arterial pressure in hypertension animal model. To reach this objective, we have used a two-kidney one clip (2K-1C) rat model. Animals received acute laser light irradiation (660 nm) on abdominal region using different energy (0.6, 1.8, 3.6, 7.2, 13.8, 28.2, 55.8, and 111.6 J), the direct arterial pressure was measured by femoral cannulation, and systolic arterial...
Tue Oct 29, 2019 02:00
Abstract This study aimed to evaluate the effect of low-level laser therapy (LLLT) on immediate postpartum pain relief during cesarean section. A randomized, parallel controlled trial was carried out. In total, 88 women with immediate postpartum were divided into 4 groups: control group (n = 22), placebo group (n = 22), experimental group I (n = 22, dose of 4 J/cm2), and experimental group II (n = 22, dose of 2 J/cm2). The pain measured by Numeric Rating Scale (NRS), algometry,...
Mon Oct 28, 2019 02:00
Toxins, Vol. 11, Pages 630: Development and Characterization of Monoclonal Antibodies for the Mycotoxin Citreoviridin Toxins doi: 10.3390/toxins11110630 Authors: Chris M. Maragos Yosuke Uchiyama Naoki Kobayashi Fumichika Kominato Yoshiko Sugita-Konishi Citreoviridin (CTV) in an inhibitor of mitochondrial ATPase that has been isolated from molded yellow rice and linked to the human disease Shoshin-kakke (acute cardiac beriberi). The disease results from a deficiency of thiamine,...
02:00
Toxins, Vol. 11, Pages 628: Fusarium graminearum FgCWM1 Encodes a Cell Wall Mannoprotein Conferring Sensitivity to Salicylic Acid and Virulence to Wheat Toxins doi: 10.3390/toxins11110628 Authors: Ya-Zhou Zhang Qing Chen Cai-Hong Liu Lu Lei Yang Li Kan Zhao Mei-Qiao Wei Zhen-Ru Guo Yan Wang Bin-Jie Xu Yun-Feng Jiang Li Kong Yan-Lin Liu Xiu-Jin Lan Qian-Tao Jiang Jian Ma Ji-Rui Wang Guo-Yue Chen Yu-Ming Wei You-Liang Zheng Peng-Fei...
Tue Oct 29, 2019 02:00
Toxins, Vol. 11, Pages 629: Rapid and Differential Evolution of the Venom Composition of a Parasitoid Wasp Depending on the Host Strain Toxins doi: 10.3390/toxins11110629 Authors: Cavigliasso Mathé-Hubert Kremmer Rebuf Gatti Malausa Colinet Poirié Parasitoid wasps rely primarily on venom to suppress the immune response and regulate the physiology of their host. Intraspecific variability of venom protein composition has been documented in some species, but...
Tue Oct 29, 2019 02:00
Toxins, Vol. 11, Pages 627: Phytotoxic Metabolites Produced by Legume-Associated Ascochyta and Its Related Genera in the Dothideomycetes Toxins doi: 10.3390/toxins11110627 Authors: Wonyong Kim Weidong Chen Phytotoxins, secondary metabolites toxic to plants and produced by fungi, are believed to play an important role in disease development by targeting host cellular machineries and/or interfering with host immune responses. The Ascochyta blight diseases on different legume plants...
Tue Oct 29, 2019 02:00
Toxins, Vol. 11, Pages 626: Spider Knottin Pharmacology at Voltage-Gated Sodium Channels and Their Potential to Modulate Pain Pathways Toxins doi: 10.3390/toxins11110626 Authors: Yashad Dongol Fernanda Caldas Cardoso Richard J Lewis Voltage-gated sodium channels (NaVs) are a key determinant of neuronal signalling. Neurotoxins from diverse taxa that selectively activate or inhibit NaV channels have helped unravel the role of NaV channels in diseases, including chronic pain. Spider...
Tue Oct 29, 2019 02:00
Toxins, Vol. 11, Pages 625: The Sequence and a Three-Dimensional Structural Analysis Reveal Substrate Specificity Among Snake Venom Phosphodiesterases Toxins doi: 10.3390/toxins11110625 Authors: Ullah Ullah Ali Betzel ur Rehman (1) Background. Snake venom phosphodiesterases (SVPDEs) are among the least studied venom enzymes. In envenomation, they display various pathological effects, including induction of hypotension, inhibition of platelet aggregation, edema, and paralysis....
Mon Oct 28, 2019 02:00
Toxins, Vol. 11, Pages 624: Analysis of the Use of Cylindrospermopsin and/or Microcystin-Contaminated Water in the Growth, Mineral Content, and Contamination of Spinacia oleracea and Lactuca sativa Toxins doi: 10.3390/toxins11110624 Authors: Maria Llana-Ruiz-Cabello Angeles Jos Ana Cameán Flavio Oliveira Aldo Barreiro Joana Machado Joana Azevedo Edgar Pinto Agostinho Almeida Alexandre Campos Vitor Vasconcelos Marisa Freitas Cyanobacteria and cyanotoxins...
Mon Oct 28, 2019 02:00
Toxins, Vol. 11, Pages 623: Venom Diversity and Evolution in the Most Divergent Cone Snail Genus Profundiconus Toxins doi: 10.3390/toxins11110623 Authors: Giulia Fassio Maria Vittoria Modica Lou Mary Paul Zaharias Alexander E. Fedosov Juliette Gorson Yuri I. Kantor Mandё Holford Nicolas Puillandre Profundiconus is the most divergent cone snail genus and its unique phylogenetic position, sister to the rest of the family Conidae, makes it a key taxon for examining...
Mon Oct 28, 2019 02:00
TOKYO--(BUSINESS WIRE)-- #NMOSD--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for satralizumab (development code: SA237), an anti-interleukin-6 (IL-6) receptor humanized recycling antibody, for the treatment of adult and adolescent patients with neuromyelitis optica spectrum disorder (NMOSD). EMA has granted Accelerated Assessment status for satralizumab. The U.S. Food and Drug Administration...
08:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for satralizumab for the treatment of adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD). The European Medicines Agency (EMA) has also validated the company’s Marketing Authorization Application (MAA) for satralizumab, granting it A
08:00
FOSTER CITY, California y SHANGHÁI--(BUSINESS WIRE)--Terns Pharmaceuticals, Inc., una compañía biofarmacéutica global enfocada en descubrir y desarrollar terapias innovadoras para tratar la esteatohepatitis no alcohólica (non-alcoholic steatohepatitis, NASH) y el cáncer, ha anunciado hoy que TERN-101, un agonista en investigación del receptor X farnesoide (farnesoid X receptor, FXR), ha recibido la designación de vía rápida (Fast Track) de la Administración de Medicamentos y Alimentos de Estado
05:06
FOSTER CITY, Californië & SHANGHAI--(BUSINESS WIRE)--Terns Pharmaceuticals, Inc., een wereldwijd opererend biofarmaceutisch bedrijf dat zich concentreert op het ontdekken en het ontwikkelen van innovatieve therapie om niet-alcoholische steatohepatitis (NASH) en kanker te behandelen, kondigde vandaag aan dat TERN-101, een onderzoeks farnesoïde de receptor van X receptor (FXR) agonist, de Fast Track Designation van de U.S. Food and Drug Administration (FDA) voor de behandeling van NASH heeft gekr
05:05
FOSTER CITY, Californie et SHANGHAI--(BUSINESS WIRE)--Terns Pharmaceuticals, Inc., une entreprise biopharmaceutique internationale axée sur la découverte et le développement de thérapies innovantes pour traiter la stéatohépatite non alcoolique (non-alcoholic steatohepatitis (NASH)) et le cancer, a annoncé aujourd’hui que TERN-101, un agoniste du récepteur farnesoid X (farnesoid X receptor, FXR), s’est vu octroyer la désignation Fast Track par la Food and Drug Administration (FDA) des États-Unis
04:58
FOSTER CITY, Kalifornien (USA), und SHANGHAI (China)--(BUSINESS WIRE)--Terns Pharmaceuticals, Inc., ein global tätiges biopharmazeutisches Unternehmen, das sich auf die Entdeckung und Entwicklung innovativer Therapien zur Behandlung von nichtalkoholischer Steatohepatitis (NASH) und Krebs konzentriert, hat heute bekannt gegeben, dass TERN-101, ein in der Erprobung befindlicher FXR-Agonist (Farnesoid-X-Rezeptor), den Fast-Track-Status für die Behandlung von NASH von der US-amerikanischen Arzneimi
04:57
BARCELONA, Spanje--(BUSINESS WIRE)--Contractonderzoeksorganisaties (CRO’s) boeken aanzienlijke vooruitgang in het bevorderen van de industriële stap om de prestaties van klinische studies te verbeteren, volgens het Veeva 2019 Unified Clinical Operations Survey: Annual CRO-Report, een van de grootste onderzoeken ooit naar professionals op het gebied van klinische operaties wereldwijd. De bevindingen van Veeva Systems (NYSE: VEEV) laten zien dat CRO’s handmatige processen elimineren en belangrijk
01:53
BARCELONE, Espagne--(BUSINESS WIRE)--Les organisations de recherche sous contrat (ORC) sont en train de réaliser des progrès significatifs afin d’aider l’industrie à améliorer les performances des essais cliniques, selon les conclusions du rapport intitulé « Veeva 2019 Unified Clinical Operations Survey: Annual CRO Report », l’une des plus importantes enquêtes jamais réalisées auprès de professionnels spécialisés dans les opérations cliniques à l’échelle mondiale. Les conclusions de Veeva Syste
01:30
BARCELONA, Spanien--(BUSINESS WIRE)--Auftragsforschungsinstitute (CROs) machen bedeutende Fortschritte, was die branchenweiten Bemühungen zur Leistungsverbesserung klinischer Studien betrifft. Dies ergibt sich aus dem Veeva 2019 Unified Clinical Operations Survey: Annual CRO Report, einer der größten jemals unter klinischen Fachleuten durchgeführten Umfragen. Die Ergebnisse von Veeva Systems (NYSE: VEEV) zeigen, dass CROs manuelle Prozesse eliminieren und Schlüsselbereiche beim Durchführen klin
01:22
NEW YORK--(BUSINESS WIRE)--First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma
Tue Oct 29, 2019 22:30
BARCELLONA, Spagna--(BUSINESS WIRE)--Le CRO stanno compiendo progressi considerevoli nel promuovere l’avanzamento del settore verso il miglioramento delle prestazioni delle sperimentazioni cliniche, come rivela il Sondaggio unificato sulle attività cliniche 2019 di Veeva: relazione annuale sulle CRO (Veeva 2019 Unified Clinical Operations Survey: Annual CRO Report), una delle indagini di più ampio respiro che sia mai stata condotta a livello globale tra i professionisti del ramo delle attività
Tue Oct 29, 2019 22:22
BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of its previously announced initial public offering of 10,997,630 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares, at a public offering price of $19.00 per s
Tue Oct 29, 2019 22:05
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2019. The Company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities and progress with its late-stage oncology portfolio. “We are executing on our vision of becoming a multi-product global oncology company, recently achieving several important milestones across our late-stage pipeline,”
Tue Oct 29, 2019 22:02
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today presented new preclinical data for SY-5609, its highly-selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7). The data demonstrate that SY-5609 induces deep and sustained anti-tumor activity, including complete regressions, in multiple preclinical models of solid tumors at doses below the maximum tolerated dose (MTD). The
Tue Oct 29, 2019 22:01
BURLINGTON, Mass.--(BUSINESS WIRE)---- $ARQL #arql--ArQule, Inc. (Nasdaq: ARQL), today announced new clinical and preclinical data demonstrating the potential of the company’s AKT inhibitor ARQ 751 in treating solid tumors characterized by mutations in the PI3K/AKT/mTOR pathway. The findings were detailed in two poster presentations at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. “Traditional tumor biopsies used to identify tumor mutational status...
Tue Oct 29, 2019 22:01
SAN ANTONIO--(BUSINESS WIRE)--New Research Study Points to Phoenix Biotech's Oleandrin for Potential to Treat HTLV-1 virus which affects 10 million-15 million worldwide
Tue Oct 29, 2019 19:40
SAN MATEO, Calif.--(BUSINESS WIRE)--Levita Magnetics, a company dedicated to improving surgical outcomes through Magnetic Surgery®, today announced that the 1,000th procedure using Magnetic Surgery has been performed. The platform represents one of the key surgical advancements in the last decade. Indicated to grasp and retract organs in certain surgical procedures, including bariatric surgery, gallbladder removal, and prostate removal, Magnetic Surgery facilitates access and visualization of t
Tue Oct 29, 2019 18:59
BARCELONA, Spain--(BUSINESS WIRE)--Veeva 2019 Unified Clinical Ops Survey: Annual CRO Report reveals that CROs are making significant progress to improve clinical trial performance.
Tue Oct 29, 2019 18:35
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #RareDisease--Newron Pharmaceuticals is sponsoring the largest qualitative study ever to examine the burden of Rett syndrome on individuals and caregivers.
Tue Oct 29, 2019 18:3
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου